Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III (ATIII), accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes (unstable angina, NSTEMI, STEMI),Anticoagulation during cardiac/vascular surgery, hemodialysis, and extracorporeal circulation,Off-label: Prevention of recurrent miscarriage associated with antiphospholipid syndrome
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous: Initial bolus of 5,000 units followed by continuous infusion of 13-21 units/kg/hour (typically 1,000-2,000 units/hour) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours for prophylaxis; 10,000-20,000 units every 12 hours for treatment.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal elimination half-life: 1-2 hours (dose-dependent, saturable clearance); prolonged to 2-6 hours in renal impairment, obese patients, or with high doses; clinical anticoagulant effect may persist 2-4 hours after a single IV bolus.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Heparin undergoes hepatic metabolism (desulfation) and is partially depolymerized; clearance is via reticuloendothelial system and renal excretion.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Primarily renal (via reticuloendothelial system); 40-50% excreted unchanged in urine; 20-30% metabolized to uroheparin and excreted renally; minor biliary (<5%).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Heparin binds extensively to antithrombin III (AT-III) and multiple plasma proteins including histidine-rich glycoprotein, platelet factor 4, vitronectin, fibronectin, and lipoproteins; very high overall protein binding (nearly 100% to AT-III when bound, but free fraction varies due to competition).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Vd approximately 0.03-0.10 L/kg (largely confined to plasma volume; limited extravascular distribution); increased Vd in pregnancy, obesity, and nephrotic syndrome.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
SC: 80-93% relative to IV (due to first-pass hepatic metabolism and local degradation); IV: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No specific dose adjustment for GFR; monitor a PTT closely in renal impairment (Cr Cl <30 m L/min) due to increased bleeding risk. For continuous infusion, consider lower initial rates (e.g., 13 units/kg/hour) and titrate carefully.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No established guidelines; use with caution in Child-Pugh B or C due to coagulopathy and decreased antithrombin III levels. Monitor a PTT more frequently.
No dosage adjustment required for hepatic impairment.
Intravenous: Bolus 50-100 units/kg, then continuous infusion 15-25 units/kg/hour. Subcutaneous: 50-100 units/kg every 6-8 hours for prophylaxis; 100-150 units/kg every 6 hours for treatment. Titrate to age-appropriate a PTT (e.g., 60-85 seconds in neonates).
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Lower initial doses (e.g., 50-70% of usual) with careful titration; increased risk of bleeding due to altered clearance. Monitor a PTT and renal function closely.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Spinal/epidural hematomas: Risk hemiparesis or paralysis with neuraxial anesthesia or spinal puncture, especially in patients on anticoagulants or with indwelling catheters.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Hemorrhage risk (monitor for bleeding; adjust dose based on a PTT),Heparin-induced thrombocytopenia (HIT) Type II (immune-mediated, monitor platelets),HIT Type I (non-immune thrombocytopenia),Hyperkalemia due to aldosterone suppression (risk in renal impairment, diabetes, or K+-sparing drugs),Heparin resistance (low ATIII levels),Osteoporosis with long-term use (>6 months)
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Severe thrombocytopenia (including HIT),Active major bleeding or bleeding diathesis (e.g., hemophilia, severe liver disease),Hypersensitivity to heparin or pork products,History of HIT or HIT with thrombosis,Use for spinal/epidural anesthesia in patients with indwelling epidural catheter (relative to black box warning),Severe uncontrolled hypertension or recent brain/spinal cord surgery (relative)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. However, vitamin K-rich foods (e.g., leafy greens) may antagonize effects if given with warfarin; heparin effect is not vitamin K-dependent.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Pregnancy category C. Heparin does not cross the placenta; no risk of fetal teratogenesis. However, increased risk of maternal bleeding, which may indirectly affect fetal well-being. Use only if clearly needed.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Heparin is not excreted into breast milk due to high molecular weight and protein binding; M/P ratio not applicable. Considered compatible with breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy increases volume of distribution and clearance, leading to lower plasma heparin levels. Dose adjustments may be needed to maintain therapeutic a PTT/anti-Xa levels; more frequent monitoring recommended.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Heparin is an anticoagulant used for prophylaxis and treatment of thromboembolic disorders. Monitor a PTT closely; therapeutic range typically 1.5-2.5 times control. Avoid intramuscular administration due to risk of hematoma. Use with caution in renal impairment. Protamine sulfate is the antidote for heparin overdose.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Do not take aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, bruising, or dark stools immediately.,Use a soft toothbrush and electric razor to avoid cuts.,Keep all appointments for blood tests to monitor your therapy.,Wear a medical alert bracelet indicating you are on heparin.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III (ATIII), accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous: Initial bolus of 5,000 units followed by continuous infusion of 13-21 units/kg/hour (typically 1,000-2,000 units/hour) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours for prophylaxis; 10,000-20,000 units every 12 hours for treatment.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy category C. Heparin does not cross the placenta; no risk of fetal teratogenesis. However, increased risk of maternal bleeding, which may indirectly affect fetal well-bein. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.